MedTech Strategist Issue: Vol. 6, No. 7 - May 15, 2019


Already a Subscriber?


Not a Subscriber?

Device-Pharma Convergence - “LEO Science & Tech Hub: A New Model for Cross-Industry Innovation”

By Mary Stuart, Senior Writer/Market Analyst

To realize its goal of accessing external innovation, LEO Pharma faces several challenges; it’s focused solely on dermatology, and as a mid-sized specialty pharma, it has to be choosy about the acquisitions it makes. It’s addressing those challenges through its Cambridge-based LEO Science & Tech Hub, which aims to be the partner of choice for medtech innovators.



Executive Interview - “Hot Topics in Cardiovascular Devices: A Conversation with Michael John”

By Mary Thompson, Executive Editor

Michael John, who is leading MCRA’s new Cardio division, speaks out on the latest trends and challenges in the cardiovascular device arena, including the outlook for transcatheter valve devices; the current paclitaxel controversy in the periphery; and the potential impact of wearable, remote CV monitoring technologies.

Orthopedics - “Orthopedic ASC Market Growth Inevitable, Despite CMS TKA Ruling”

By Wendy Diller, Senior Writer/Market Analyst

Orthopedics and spine surgery procedures are starting to migrate to outpatient settings, ambulatory surgery centers in particular. Medtech companies are thinking about how to best to gear up for the change.



Platelet Production - “Platelet BioGenesis: Getting Platelets to Patients on Time and at Cost”

By Wendy Diller, Senior Writer/Market Analyst

Using recently discovered cell culture techniques and an innovative bioreactor, Platelet BioGenesis is closing a weak link in our blood supply chain by offering on-demand production of platelets at affordable prices.

Pain Management - “Sana Health: Pain Relieved, Not Just Masked”

By Colin Miller, Contributing Writer

As an alternative to opioids for severe and chronic pain, the risks of which are well documented, Sana Health has developed a mask that uses a protected algorithm to issue audiovisual stimulation that puts users in a relaxed, therapeutic “flow state” and promotes neuroplasticity for prolonged pain reduction.

Sana Health device.png

Vascular Monitoring.jpeg

Vascular Monitoring - “Sonavex: Post-Op Monitoring in Three Dimensions”

By Colin Miller, Senior Writer/Market Analyst

Reconstructive surgery poses a high risk, in the immediate postoperative period, of clots developing in the small blood vessels that connect transplanted tissue. Sonavex aims to provide detailed yet simplified visual and quantitative information on blood flow to detect vascular compromise while there is time to intervene and salvage the tissue successfully.

Not a Subscriber?

Already a Subscriber?

Want a Sample Article?

Companies Covered in this Issue: Abbott Laboratories Inc., Aetna Inc., Apple Inc., BD/Bard, Boston Scientific Corp., Edwards Lifesciences Corp., Elektrofi, Epicore Biosystems, Globus Medical Inc., Johnson & Johnson, LEO Pharma AS, LEO Science & Tech Hub, Megakaryon Corp., Muve Health, Novopyxs, Platelet BIoGenesis Inc., PRM Life Sciences, Reflexion Health Inc., RTI Surgical Holdings Inc., Sana Health Inc., Sanofi-Genzyme, Sonavex Inc., Stryker Corp., UnitedHealth Group, Wearifi, Zimmer Biomet

Topics Covered in this Issue: Aesthetics/Dermatology; Business Strategies; Cardiovascular/Vascular; Critical Care/Emergency Medicine/ICU; Digital Health, Executive Interviews; Investors & Dealmaking; Neurology/Neurovascular; Orthopedics/Spine; Providers & Payors; Regulatory & Reimbursement; Surgery/Robotics; Start-Ups to Watch